Sanofi and Lexicon have teamed up on the development of a new diabetes drug that can treat both type 1 diabetes and type 2 diabetes. The new medication, known chemically as sotagliflozin, is in a class of diabetes drugs known as SGLT2 inhibitors, which also includes the brand name medications Invokana, Invokamet, Farxiga and Jardiance. Most type 2 diabetes medications work through the pancreas and liver. SGLT2 inhibitors work differently, blocking the absorption of glucose in the kidneys, allowing patients to excrete excess glucose through their urine. Sotagliflozin also works by targeting SGLT1 inhibitors located in the intestinal tract. SGLT2 ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.